Page last updated: 2024-11-13

kaliotoxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

kaliotoxin: peptidyl inhibitor of neuronal BK-type calcium-activated K+ channels from Androctonus mauretanicus mauretanicus venom; MW 4 kDa; amino acid sequence has been determined [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID90488859
MeSH IDM0195888

Synonyms (5)

Synonym
kaliotoxin
145199-73-1
AKOS024457688
J-008070
PD079558

Research Excerpts

Overview

Kaliotoxin (KTX) is a neurotoxin purified from Androctonus scorpion venom. It is a natural peptide blocker of voltage-dependent K+ channels.

ExcerptReferenceRelevance
"Kaliotoxin2 (KTX2) is a highly selective blocker of voltage-dependent potassium channels Kv1.3 containing 37 amino acid residues. "( Evaluation of neuroprotective effects of insulin on immuno-inflammatory and systemic disorders induced by kaliotoxin, a Kv1.3 channel blocker.
Laraba-Djebari, F; Martin-Eauclaire, MF; Taibi-Djennah, Z, 2018
)
2.14
"Kaliotoxin (KTX) is a neurotoxin purified from Androctonus scorpion venom. "( Neuropathophysiological effect and immuno-inflammatory response induced by kaliotoxin of androctonus scorpion venom.
Ladjel-Mendil, A; Laraba-Djebari, F; Martin-Eauclaire, MF, 2013
)
2.06
"Kaliotoxin (KTX) is a natural peptide blocker of voltage-dependent K+ channels. "( 3D structure of kaliotoxin: is residue 34 a key for channel selectivity?
Fernández, I; Gairí, M; Giralt, E; Martin-Eauclaire, MF; Pons, M; Rochat, H; Romi, R; Van Rietschoten, J,
)
1.92

Effects

ExcerptReferenceRelevance
"Kaliotoxin (KTX) has been originally described as an inhibitor of the intermediate conductance Ca(2+)-activated K+ channel (Crest, M., Jacquet, G., Gola, M., Zerrouk, H., Benslimane, A., Rochat, H., Mansuelle, P., and Martin-Eauclaire, M.-F. "( The kaliotoxin family enlarged. Purification, characterization, and precursor nucleotide sequence of KTX2 from Androctonus australis venom.
Céard, B; Crest, M; Gola, M; Jacquet, G; Laraba-Djebari, F; Legros, C; Mansuelle, P; Rochat, H; Romi, R; van Rietschoten, J, 1994
)
2.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (59)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's26 (44.07)18.2507
2000's23 (38.98)29.6817
2010's9 (15.25)24.3611
2020's1 (1.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.79 (24.57)
Research Supply Index4.11 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other60 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]